Estrogen receptor beta increases clear cell renal cell carcinoma stem cell phenotype via altering the circPHACTR4/miR‐34b‐5p/c‐Myc signaling. Issue 2 (21st January 2022)

• Record Type: Journal Article
• Authors: Wang, Yaxuan; Yang, Zhan; Gu, Junfei; Zhang, Yanping; Wang, Xin; Teng, Zhihai; Wang, Dandan; Gao, Lei; Li, Wei; Yeh, Shuyuan; Han, Zhenwei
• Is Part Of: FASEB journal. Volume 36:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-21
• Subjects: circular RNA -- CSCs -- estrogen receptor beta -- miRNA -- renal cell carcinoma; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.202101645R
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: Early clinical studies indicated that estrogen receptor beta (ERβ) might play key roles to impact the progression of clear cell renal cell carcinoma (ccRCC). The detailed molecular mechanisms, however, remain unclear. Here, we found ERβ could increase the cancer stem cell (CSC) population via altering the circPHACTR4/miR‐34b‐5p/c‐Myc signaling. Mechanism dissection revealed that ERβ could suppress circular RNA PHACTR4 (circPHACTR4) expression via direct binding to the estrogen response elements (EREs) on the 5′ promoter region of its host gene, phosphatase and actin regulator 4 ( PHACTR4 ) to decrease miR‐34b‐5p expression. The decreased miRNA‐34b‐5p could then increase c‐Myc mRNA translation via targeting its 3′ untranslated region (3′ UTR). The in vivo mouse model with subcutaneous xenografts of ccRCC cells also validated the in vitro data. Importantly, analysis results from ccRCC TCGA database and our clinical data further confirmed the above in vitro/in vivo data. Together, these results suggest that ERβ may increase CSC population in ccRCC via altering ERβ/circPHACTR4/miR‐34b‐5p/c‐Myc signaling and that targeting this newly identified signal pathway may help physicians to better suppress ccRCC progression.